Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

This study is testing whether a medication that targets the noradrenaline (norepinephrine) system in the brain can reduce "freezing of gait" in Parkinson's disease — sudden episodes where a person with Parkinson's suddenly cannot move their feet, as if glued to the floor. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of idiopathic Parkinson's disease - You experience freezing of gait on a daily basis - You are stable on your current Parkinson's medications for at least four weeks - You can walk 10 meters without assistance when your medication is working **You may NOT be eligible if...** - You have a pacemaker, deep brain stimulator, or metal implants that prevent MRI - You have another condition that significantly affects your walking (such as severe joint or bone problems) - You have severe dementia or active psychosis - You have severe high blood pressure, heart failure, or other serious heart conditions - You are currently participating in another clinical trial Talk to your doctor to see if this trial is right for you.